Clinical Trial Update: Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update indicating that Substudy 06C is evaluating pembrolizumab in combination with chemotherapy for first-line locally advanced unrese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Adenocarcinoma
• Gastroesophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING